GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ocular Therapeutix
Ocular Therapeutix develops treatments for eye diseases based on its hydrogel platform. Its stock price is highly volatile and depends on clinical trial results and FDA decisions regarding its products, as is typical for the biotech sector.
Share prices of companies in the market segment - Pharma eyes
Ocular Therapeutix is a biopharmaceutical company specializing in the treatment of eye diseases using a hydrogel drug delivery platform. We classify it as part of the Pharma Eyes sector, and the chart below shows the overall performance of biotech companies in the ophthalmology sector.
Broad Market Index - GURU.Markets
Ocular Therapeutix is a biopharmaceutical company developing treatments for eye diseases based on its hydrogel implant technology. Its innovative platform makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Ocular compares to it.
Change in the price of a company, segment, and market as a whole per day
OCUL - Daily change in the company's share price Ocular Therapeutix
The daily price change of Ocular Therapeutix, an ophthalmology innovator, reflects the inherent volatility of the biotech industry. change_co shows the stock's sensitivity to research results and regulatory decisions. This metric serves as an important input for comprehensive risk analysis in the pharmaceutical industry on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Ocular Therapeutix, Inc. is a biopharmaceutical company. This chart highlights the sector's extreme volatility. Comparing it to OCUL, which focuses on eye care, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Ocular Therapeutix is a biopharmaceutical company specializing in the treatment of eye diseases using innovative drug delivery systems. Ophthalmology is a highly specialized and competitive field. The chart below shows volatility in this sector, allowing you to assess how Ocular shares react to industry news.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ocular Therapeutix
Ocular Therapeutix is a biopharmaceutical company specializing in the treatment of eye diseases. Its stock price depends on the success of its products in commercialization and regulatory approvals. These events create unique price movements.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the development of innovative drugs for the treatment of eye diseases. Its unique hydrogel platform enables prolonged drug delivery. The graph shows how its technology and clinical success are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ocular Therapeutix is a biopharmaceutical company whose stock performance is driven by sales success of its eye care products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ocular Therapeutix
Ocular, a biopharmaceutical company developing drugs for the treatment of eye diseases. Monthly fluctuations on the chart reflect the commercial success of its approved products and news about clinical trials of new candidates in its portfolio.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Developing drugs to treat eye diseases is a highly specialized area of biotechnology. The dynamics of this segment, visible in the chart, reflect investors' confidence in new therapeutic methods and drug delivery systems. In this environment, innovators like Ocular Therapeutix are conducting their clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ocular Therapeutix develops drugs to treat eye diseases. Like many biotechs, its stock price is driven by regulatory announcements and research data. The chart shows how these events trigger sharp movements unrelated to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ocular Therapeutix
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases based on its hydrogel platform. The company's weekly stock price is driven by sales reports for its approved product and, to a greater extent, by news of clinical trials for new candidates.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Ocular Therapeutix, as a biopharmaceutical company with a single core product and several candidates, can move differently than diversified giants. The successful launch and sales growth of its drug is a unique driver. The chart allows for comparison with the broader pharmaceutical sector and shows how the market values a growth story focused on a single drug.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ocular Therapeutix develops drugs for the treatment of eye diseases. It's a clinical-stage biotech company, and its stock is highly volatile. The chart shows how much its weekly fluctuations are driven by development news rather than by overall market trends.
Market capitalization of the company, segment and market as a whole
OCUL - Market capitalization of the company Ocular Therapeutix
Ocular Therapeutix's market capitalization reflects its focus on developing and commercializing innovative eye treatments using a hydrogel platform. Its chart volatility is driven by clinical trial results and regulatory decisions. Investors are assessing the potential of its technology to change the standard of ophthalmological care.
OCUL - Share of the company's market capitalization Ocular Therapeutix within the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using its hydrogel implant technology. Its market share reflects both its already approved products and the potential for extended-release developments.
Market capitalization of the market segment - Pharma eyes
Here's a chart showing the market capitalization of the ophthalmic pharmaceutical sector. Ocular Therapeutix develops innovative drug delivery systems for the eye, such as hydrogel implants. The potential of this market is enormous, and Ocular aims to change the standard of care for conditions such as glaucoma and post-operative inflammation.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ocular Therapeutix has developed a platform for delivering medications directly to the eye, eliminating the need for frequent injections and eye drops. Its market capitalization reflects the potential of this technology in ophthalmology. The chart below shows the economic impact of innovative drug delivery.
Book value capitalization of the company, segment and market as a whole
OCUL - Book value capitalization of the company Ocular Therapeutix
Ocular Therapeutix's foundation is its intellectual property (IP) for its hydrogel platform for ocular drug delivery and its commercial product, DEXTENZA. The chart shows how the biotech company, after receiving approval for one product, uses revenue and raises capital to expand the application of its unique technology.
OCUL - Share of the company's book capitalization Ocular Therapeutix within the market segment - Pharma eyes
Ocular Therapeutix creates extended-release ophthalmic medications. The chart shows its share of real assets. These include its laboratories and manufacturing facilities, where unique hydrogel implants for drug delivery are developed.
Market segment balance sheet capitalization - Pharma eyes
Ocular Therapeutix develops eye treatments, and its model is becoming increasingly capital-intensive. In addition to R&D, the company is building its own manufacturing facilities to produce its hydrogel implants. This demonstrates its shift toward vertical integration in the biotech sector.
Book value of all companies included in the broad market index - GURU.Markets
Ocular Therapeutix's balance sheet isn't about drugs in vials, but rather a unique technology for delivering medications directly to the eye using hydrogel implants. The company's assets reflect the value of this innovative platform. The chart shows how much capital has been invested in a development that could change the standards of ophthalmological treatment.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ocular Therapeutix
Ocular Therapeutix develops innovative drugs for the treatment of ophthalmic diseases. The company's market capitalization is built on its proprietary hydrogel technology, which promises to revolutionize drug delivery. Investors evaluate not current assets, but the potential to change the standard of care in ophthalmology.
Market to book capitalization ratio in a market segment - Pharma eyes
Ocular Therapeutix develops drugs for the treatment of eye diseases. Its core asset is its patented drug delivery technology. This chart shows how its market capitalization, reflecting the potential of this platform, is a multiple of its book value, which consists primarily of hardware.
Market to book capitalization ratio for the market as a whole
Ocular Therapeutix develops treatments for eye diseases using its proprietary hydrogel platform technology. The company's market capitalization is based on the potential of this unique drug delivery technology. This chart shows how the market values the innovative scientific platform, not the company's tangible assets.
Debts of the company, segment and market as a whole
OCUL - Company debts Ocular Therapeutix
Ocular Therapeutix develops and commercializes ophthalmic drugs using its innovative hydrogel platform technology. Funding is needed to conduct clinical trials of new products and expand commercialization of those already approved. This schedule reflects investments in the company's future growth.
Market segment debts - Pharma eyes
Ocular Therapeutix develops drugs to treat eye diseases. The transition from research to commercialization requires significant investments in marketing and manufacturing. This chart shows how the company finances this transition: through revenue from already approved products or by raising additional capital to bring its innovative pipeline to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ocular Therapeutix
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases based on its hydrogel implant technology. This chart shows its financial position in the growth stage. The debt and equity levels here reflect the balance between funding sales of existing products and investing in clinical trials of new candidates.
Market segment debt to market segment book capitalization - Pharma eyes
Ocular Therapeutix develops drugs for eye diseases, which require long-term and risky investments. The chart illustrates the common debt policy in the ophthalmic pharmaceutical industry. It helps investors understand whether the company's financing strategy is typical for biotech companies focused on developing innovative treatments.
Debt to book value of all companies in the market
Ocular Therapeutix, as a pharmaceutical company, requires long-term investment. The chart shows the overall debt policy for the entire market. This helps investors understand that the financial model of such companies depends less on the short-term credit cycles reflected in the chart and more on the long-term potential of their scientific developments.
P/E of the company, segment and market as a whole
P/E - Ocular Therapeutix
This chart for Ocular Therapeutix, a company developing ocular implants for drug delivery, evaluates its innovative technology. The high price-to-earnings ratio reflects investors' belief that their approach will transform the treatment of eye diseases. The volatility reflects progress in research and product commercialization.
P/E of the market segment - Pharma eyes
This chart reflects the average valuation for the biopharmaceutical sector—a benchmark for Ocular Therapeutix. Comparing this ophthalmology-focused company's valuation to the industry average helps understand how investors view its drug delivery technology and the commercial prospects of its products.
P/E of the market as a whole
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using an innovative hydrogel platform. The company's success depends on the approval and acceptance of its products by physicians. This chart, which reflects the overall risk appetite of investors in the biotech sector, shows how much they believe in the potential of the Ocular platform.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ocular Therapeutix
Ocular Therapeutix develops and commercializes medications for the treatment of eye diseases using innovative hydrogel delivery technology. The company's future success depends on the approval and implementation of its new products. This chart shows analysts' forecasts for the commercial potential of its developments, particularly in the treatment of glaucoma and retinal diseases.
%20P%2FE%20Ocular%20Therapeutix&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ocular-Therapeutix&v=1772656474399 "Chart of the company's future (projected) P/E Ocular Therapeutix")
Future (projected) P/E of the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes ophthalmic drugs using its hydrogel delivery technology. Its valuation relative to other ophthalmology pharmaceutical companies reflects the market's opinion of its platform's potential, indicating investor confidence in its ability to transform the treatment of ophthalmic diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772656474428 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using an innovative drug delivery system. The company's success depends on the approval and adoption of its products. This chart illustrates the overall market risk appetite, which influences the valuation of biotech companies, particularly those at the intersection of pharmaceuticals and medical devices.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656474446 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ocular Therapeutix
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases based on its hydrogel implant technology. Financial results shown here are dependent on successful sales of existing products and progress in developing new ones. Its innovative drug delivery method is its key advantage.
Profit of companies in the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using its innovative hydrogel platform. This chart shows the overall profitability of ophthalmic pharmaceutical companies. It helps assess the market's willingness to accept and pay for new drug delivery technologies.
Overall market profit
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using an innovative hydrogel platform. Like many biotech companies, its success is determined by clinical results and FDA approval, rather than by broad economic trends, as illustrated by the chart on this page.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ocular Therapeutix
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using innovative drug delivery technology. Its future revenue projections depend on the success of its current products and pipeline developments. This chart shows how analysts assess the commercial potential of its platform for developing new ophthalmic drugs.
%20profit%20of%20the%20company%20Ocular%20Therapeutix&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ocular-Therapeutix&v=1772656474531 "Graph of future (projected) profit of the company Ocular Therapeutix")
Future (predicted) profit of companies in the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases based on its hydrogel implant technology, which provides sustained drug release. This chart shows forecasts for the ophthalmology segment. It helps assess the potential contribution of Ocular's innovative drug delivery platform to changing treatment standards and industry profitability.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772656474540 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Ocular Therapeutix develops and commercializes ophthalmic drugs using its innovative hydrogel platform. The overall revenue forecast reflected here influences funding for the biotech sector. Economic optimism is driving investment in companies like Ocular, allowing them to advance their developments through clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656474550 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ocular Therapeutix
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using an innovative drug delivery system. This chart shows how investors view its current sales and the potential for future products that could change the standard of care in ophthalmology.
P/S market segment - Pharma eyes
Ocular Therapeutix develops and commercializes innovative treatments for eye diseases using its hydrogel implant technology. This chart shows the average valuation in the ophthalmology sector. It helps understand how investors view the potential of Ocular's platform for developing extended-release drugs.
P/S of the market as a whole
Ocular Therapeutix is a biopharmaceutical company developing and commercializing innovative treatments for eye diseases using a hydrogel platform. Its revenue depends on the success of its existing and future products. This chart helps investors correlate the valuation of a company in a highly specialized medical niche with overall market trends.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ocular Therapeutix
Ocular Therapeutix develops and commercializes ophthalmic drugs using its hydrogel implant technology. Future revenue depends on the success of existing and future eye disease treatments. The chart shows how investors assess the platform's potential for developing innovative drugs.
%20P%2FS%20Ocular%20Therapeutix&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ocular-Therapeutix&v=1772656474810 "The graph of the company's future (projected) P/S Ocular Therapeutix")
Future (projected) P/S of the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes ophthalmic drugs based on its innovative hydrogel platform, which provides sustained drug delivery to the eye. This chart shows how the market evaluates the potential of this technology for treating eye diseases compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772656474840 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
This chart illustrates the market's confidence in ophthalmology innovation. For Ocular Therapeutix, a company developing extended-release medications for eye diseases, this reflects the investment climate. Market optimism is helping fund the development of products that could change the standard of care for conditions such as glaucoma and post-operative inflammation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656474903 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ocular Therapeutix
Ocular Therapeutix is a biopharmaceutical company developing and commercializing innovative treatments for eye diseases using its hydrogel implant technology. This chart shows revenue from sales of its products, which deliver medication to the eye over a long period of time. Growing sales reflect the acceptance of this technology by ophthalmologists.
Sales of companies in the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes medications for the treatment of eye diseases based on its hydrogel implant technology. This graph illustrates the growth of the ophthalmic market. The company offers an innovative drug delivery method that can replace traditional eye drops, improving the convenience and effectiveness of treatment.
Overall market sales
Ocular Therapeutix is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases. Its success depends on the approval and commercialization of its products. The overall economic situation, reflected in this chart, affects the availability of capital for R&D and the ability of the healthcare system to finance innovative treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ocular Therapeutix
Ocular Therapeutix develops and commercializes ophthalmic drugs based on its innovative hydrogel platform, which provides sustained drug delivery. Future sales are dependent on the success of existing and future products. This chart shows analysts' forecasts for ophthalmology market growth and physician adoption of Ocular's technology.
%20sales%20of%20the%20company%20Ocular%20Therapeutix&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ocular-Therapeutix&v=1772656475120 "Schedule of future (projected) sales of the company Ocular Therapeutix")
Future (projected) sales of companies in the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes ophthalmic drugs using its hydrogel implant technology for drug delivery. This forecast highlights expectations for the pharmaceutical sector focused on eye diseases and illustrates the future demand for the innovative treatments the company offers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772656475135 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative treatments for eye diseases. Its success depends on the approval and adoption of its products in ophthalmological practice. This graph, reflecting the overall state of the economy, influences healthcare system budgets and the market's readiness to accept new, more advanced treatment technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656475166 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ocular Therapeutix
Ocular Therapeutix develops and markets innovative implantable eye medications. The chart shows the company's financial picture, balancing sales and development. Profitability depends on sales growth of the approved product, which finances expensive research into promising new drugs.
Market segment marginality - Pharma eyes
Ocular Therapeutix develops and commercializes ophthalmic drugs based on its innovative hydrogel platform. The company's success depends on market acceptance of its technology and the expansion of its product portfolio. This chart shows the operating margin of its business model compared to other pharmaceutical companies in the ophthalmology field.
Market marginality as a whole
Ocular Therapeutix develops and commercializes ophthalmic drugs using its innovative hydrogel delivery technology. This overall profitability curve is not key for the company. The company's future profitability depends on the approval and acceptance of its products by physicians, as well as its ability to offer more convenient and effective treatments for eye diseases.
Employees in the company, segment and market as a whole
Number of employees in the company Ocular Therapeutix
Ocular Therapeutix develops and commercializes innovative treatments for eye diseases based on its hydrogel implant technology. This chart shows the team that guides treatments from the lab to the patient. The growth in staff reflects the company's transition from an R&D organization to a commercial organization.
Share of the company's employees Ocular Therapeutix within the market segment - Pharma eyes
Ocular Therapeutix develops and commercializes innovative treatments for eye diseases using a hydrogel platform. This chart shows the percentage of scientists, clinicians, and manufacturing specialists in ophthalmic pharmaceuticals that the company attracts. It reflects its focus on concentrating talent to create breakthrough ocular therapies.
Number of employees in the market segment - Pharma eyes
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative eye treatments using its proprietary hydrogel implant technology. This chart shows employment in the ophthalmic pharmaceutical sector, illustrating how new drug delivery systems can change the standard of care for eye diseases.
Number of employees in the market as a whole
Ocular Therapeutix develops and commercializes drugs for the treatment of eye diseases using an innovative delivery system. Like many biotech companies, their growth depends on successful clinical trials. They represent a sector that creates jobs for scientists, physicians, and researchers, shaping a knowledge-based economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ocular Therapeutix (OCUL)
Ocular Therapeutix develops drugs for the treatment of eye diseases based on its proprietary hydrogel platform. This chart shows how the market values this innovative drug delivery technology. The high market capitalization per employee reflects the value of their platform, which has the potential to change the standard of care in ophthalmology.
%20of%20the%20company%20Ocular%20Therapeutix%20(OCUL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ocular-Therapeutix-OCUL&v=1772656475365 "Chart of market capitalization per employee (in thousands of dollars) of the company Ocular Therapeutix (OCUL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Ocular Therapeutix (OCUL) is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases (e.g., glaucoma, dry eye) using their proprietary hydrogel delivery technology. This chart shows the average market capitalization per employee in the sector. It helps assess how the market values their drug delivery R&D platform per scientist.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772656475380 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Ocular Therapeutix is a biopharmaceutical company specializing in the treatment of eye diseases using innovative drug delivery systems. This chart reflects the market's perceived value per employee, highlighting the importance of proprietary technologies in pharmaceuticals.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656475411 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ocular Therapeutix (OCUL)
Ocular Therapeutix develops and commercializes ophthalmic drugs (for the eyes). The company already has approved products. This chart shows how efficiently their small team (R&D and sales) can produce and sell these niche, yet high-margin drugs, generating net profit.
%20Chart%20Ocular%20Therapeutix%20(OCUL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ocular-Therapeutix-OCUL&v=1772656475455 "Company Profit Per Employee (in thousands of dollars) Chart Ocular Therapeutix (OCUL)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Ocular (OCUL) is an R&D biotech (eye medications). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772656475489 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Ocular Therapeutix is a biopharmaceutical company focused on treating eye diseases using its hydrogel drug delivery platforms. They already have commercial products. This chart shows how successfully the company combines R&D and sales. It reflects the balance between development costs for new products and profits from existing ones.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656475501 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ocular Therapeutix (OCUL)
Ocular Therapeutix is a biopharmaceutical company specializing in innovative treatments for eye diseases. This graph shows the company's path from scientific research to market acceptance. This growth reflects successful product commercialization and the team's effectiveness in monetizing intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ocular-Therapeutix-OCUL&v=1772656475537 "Sales chart per company employee Ocular Therapeutix (OCUL)")
Sales per employee in the market segment - Pharma eyes
Ocular Therapeutix is a biotech company developing drugs for the treatment of eye diseases using its hydrogel drug delivery platform. This chart shows the average revenue per employee in the segment. It helps evaluate how productive Ocular's R&D and commercialization team is in ophthalmology compared to its competitors.
Sales per employee for the market as a whole
Ocular Therapeutix is a biopharmaceutical company specializing in the treatment of eye diseases using its innovative hydrogel platforms. They have approved products. This chart shows how effectively their small, highly specialized sales team promotes and sells their innovative eye medications.
Short shares by company, segment and market as a whole
Shares shorted by company Ocular Therapeutix (OCUL)
Ocular Therapeutix develops ophthalmic drugs using its hydrogel drug delivery technology (for the treatment of glaucoma and retinal diseases). This is a highly competitive market. This chart shows how many investors are betting that the company's drugs will fail to prove superior to existing treatments or receive FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ocular-Therapeutix-OCUL&v=1772656475609 "Short Shares Chart for the Company Ocular Therapeutix (OCUL)")
Shares shorted by market segment - Pharma eyes
Ocular Therapeutix, Inc. develops drugs to treat eye diseases (such as glaucoma) using its hydrogel implant technology for sustained drug delivery. This chart shows the total short position in the ophthalmic biotech sector. The high figure indicates general investor skepticism about the success of clinical trials or FDA approval in this niche.
Shares shorted by the overall market
Ocular Therapeutix (OCUL) is a biotech focused on eye diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with stable drug revenues, often experience sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ocular Therapeutix (OCUL)
Ocular Therapeutix (OCUL) is a biopharmaceutical company focused on innovative treatments for eye diseases. Their key technology is a hydrogel drug delivery platform. This chart is an oscillator that measures trend strength. It helps identify when expectations for FDA approval of a new drug are leading to overheating (above 70) or when concerns are pushing the stock into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ocular-Therapeutix-OCUL&v=1772656475656 "RSI 14 indicator chart for the company's stock Ocular Therapeutix (OCUL)")
RSI 14 Market Segment - Pharma eyes
Ocular Therapeutix (OCUL) is a biopharmaceutical company focused on treating eye diseases with its innovative hydrogel drug-delivery implants. This chart tracks the overall sentiment in the Pharma/Ophthalmology sector. It helps investors understand whether the entire biotech segment is overhyped or oversold amid setbacks, providing context for OCUL.
RSI 14 for the overall market
Ocular Therapeutix (OCUL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OCUL (Ocular Therapeutix)
Ocular Therapeutix is a biopharmaceutical company that uses its hydrogel platform to deliver drugs to the eye, treating glaucoma and post-operative inflammation. This chart represents the collective opinion of experts on the 12-month price of OCUL shares, based on the success of its developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OCUL-Ocular-Therapeutix&v=1772656475830 "A chart showing analyst consensus forecasts for the expected stock price. OCUL (Ocular Therapeutix)")
The difference between the consensus estimate and the actual stock price OCUL (Ocular Therapeutix)
Ocular Therapeutix (OCUL) is a biopharmaceutical company specializing in the treatment of eye diseases using its hydrogel implant technology (Dextenza). This chart shows the valuation of their technology. It measures the gap between the price and the consensus target, reflecting analysts' confidence in the success of their retinal R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OCUL-Ocular-Therapeutix&v=1772656475888 "A chart showing the difference between the consensus forecast and the actual stock price. OCUL (Ocular Therapeutix)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Ocular Therapeutix is a biopharmaceutical company developing innovative methods for delivering drugs to the eye (such as absorbable implants) to replace eye drops. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe there is demand for more convenient treatments for eye diseases.
Analysts' consensus forecast for the overall market share price
Ocular Therapeutix (OCUL) is a biotech company specializing in delivering drugs to the eye (via implants). This chart of overall market sentiment is important. Optimism = the market is willing to fund R&D. But OCUL already has a product, so during a recession (pessimism), investors may appreciate the non-cyclical nature of demand for eye treatments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ocular Therapeutix
Ocular Therapeutix (OCUL) is an ophthalmology company developing innovative drug delivery systems (hydrogels) for the treatment of ocular diseases such as glaucoma and dry eye. This chart evaluates their R&D platform. It reflects the commercial success of their first product and the expectations for their extensive pipeline, which promises to replace daily eye drops with infrequent injections.
AKIMA Market Segment Index - Pharma eyes
Ocular Therapeutix (OCUL) is a single-product biotech (currently); the company has developed a unique technology for drug delivery to the eye (hydrogel) for the treatment of eye diseases (Dextenza). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does OCUL's technological (delivery) platform differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
Ocular Therapeutix is a biopharmaceutical company developing methods for delivering medications to the eye (hydrogel implants). The goal is to replace eye drops. This chart, reflecting the market average, provides context. It helps assess how this innovative ophthalmology story fits in with the overall macroeconomic trends impacting the healthcare sector.
